Shares of Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) have received a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Analysts have set a 12-month consensus price target of $24.00 for the company and are predicting that the company will post ($0.55) earnings per share for the current quarter, according to Zacks. Zacks has also given Aeglea Bio Therapeutics an industry rank of 182 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research upgraded Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating and set a $5.50 target price for the company in a report on Friday, November 10th.
In other news, CFO Charles N. York II acquired 25,959 shares of the firm’s stock in a transaction dated Tuesday, December 5th. The stock was purchased at an average price of $4.48 per share, for a total transaction of $116,296.32. Following the completion of the acquisition, the chief financial officer now directly owns 10,828 shares in the company, valued at approximately $48,509.44. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Charles N. York II acquired 6,500 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were purchased at an average price of $4.59 per share, with a total value of $29,835.00. Following the acquisition, the chief financial officer now owns 10,828 shares of the company’s stock, valued at $49,700.52. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 57,691 shares of company stock valued at $269,483. Corporate insiders own 27.00% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in AGLE. Renaissance Technologies LLC grew its holdings in Aeglea Bio Therapeutics by 150.8% during the fourth quarter. Renaissance Technologies LLC now owns 32,100 shares of the biotechnology company’s stock worth $174,000 after buying an additional 19,300 shares in the last quarter. Vanguard Group Inc. grew its holdings in Aeglea Bio Therapeutics by 9.4% during the second quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock worth $579,000 after buying an additional 12,966 shares in the last quarter. Finally, Jennison Associates LLC grew its holdings in Aeglea Bio Therapeutics by 0.6% during the fourth quarter. Jennison Associates LLC now owns 1,393,439 shares of the biotechnology company’s stock worth $7,539,000 after buying an additional 8,372 shares in the last quarter. Hedge funds and other institutional investors own 47.04% of the company’s stock.
Shares of Aeglea Bio Therapeutics (AGLE) traded up $0.23 during mid-day trading on Friday, reaching $6.31. The company’s stock had a trading volume of 57,200 shares, compared to its average volume of 82,017. The company has a market capitalization of $101.20, a P/E ratio of -3.45 and a beta of 2.99. Aeglea Bio Therapeutics has a 1-year low of $2.81 and a 1-year high of $8.14.
ILLEGAL ACTIVITY NOTICE: This story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/02/21/aeglea-bio-therapeutics-inc-agle-receives-consensus-recommendation-of-strong-buy-from-brokerages.html.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.
Get a free copy of the Zacks research report on Aeglea Bio Therapeutics (AGLE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.